Russia's Sputnik V Covid-19 Vaccine To Be Produced In India

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), and Hetero, one of India’s leading generic pharma companies (through its biologics arm “Hetero Biopharma”), have agreed to produce in India over 100 million doses per year of the world’s first registered vaccine against the novel coronavirus infection — Sputnik V.

The parties plan to start the production of Sputnik V in the beginning of 2021. The Gamaleya Center and RDIF announced on November 24 positive results obtained during the second interim data analysis of the largest double-blind, randomised, placebo-controlled Phase III clinical trials in Russia’s history involving 40,000 volunteers.

Interim trial results have once again confirmed the high efficacy of the Sputnik V vaccine, the world’s first registered vaccine against coronavirus based on a well-studied platform of human adenoviral vectors.

Comments

Popular posts from this blog

EzyStayz Kicks Off Its First Exchange Listing With Foblgate

ETF Securities offers Australian investors first access to India growth story

Vivo V20 Pro India Launch Confirmed for December 2: Expected Price, Specifications